Angiopoietin-like proteins - their role in lipoprotein metabolism and association with atherogenic dyslipidemia

Scientists have been trying to find the best parameter for laboratory assessment of the risk of cardiovasculardiseases (CVD) for decades. Initially, the results of many studies indicated that the analysisof the lipid profile was sufficient to evaluate the risk of CVD. Further studies revealed that more preciselaboratory prediction of cardiovascular risk requires quantification of atherogenic lipoproteins. Recently,angiopoietin-like proteins 3, 4 and 8 (ANGPTLs) have been described as important regulators of plasmalipoprotein metabolism and triglyceride homeostasis. Mutations in ANGPTL3 leading to loss of its functionhave been linked to decreased risk of CVD in humans. Among potential new targets for the managementof dyslipidemia, ANGPTL3 may become a considerably promising one